Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Covista Inc.DV · Entity 3964 | Director | November 10, 2016 | November 14, 2016 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | March 31, 2025 | April 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Covista Inc.
Report date November 10, 2016 · Filed November 14, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,057 |
Reported balance
After 2016-11-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-11-10 · Grant · Acquired 3,640 · Balance 15,057 F1: The common stock is a restricted stock unit which represents a right to receive one share of common stock for each restricted stock unit. Stock units vest 100% on the one year anniversary of the transaction date. |
Filing footnotes · ownership attribution and instrument terms
F1: The common stock is a restricted stock unit which represents a right to receive one share of common stock for each restricted stock unit. Stock units vest 100% on the one year anniversary of the transaction date.
ZIMMER BIOMET HOLDINGS, INC.
Report date March 31, 2025 · Filed April 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $112.51 | Direct | 21,937.582 |
Reported balance
After 2025-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-31 · Grant · Acquired 533.286 · Balance 21,937.582 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4: Includes 45.338 phantom stock units accrued on January 31, 2025 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.
F4: Includes 45.338 phantom stock units accrued on January 31, 2025 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date April 30, 2004 · Filed May 04, 2004
Section 16 reporting ended · disclosed 2004-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 240,618 |
Reported balance
After 2004-04-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2004-04-30 · Tax withholding · Disposed 3,506 · Balance 240,618 |
| Common SharesSEC Table I · non-derivative | Direct | 230,075 |
Reported balance
After 2004-04-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2004-04-30 · Tax withholding · Disposed 10,543 · Balance 230,075 |
| Common SharesSEC Table I · non-derivative | Direct | 222,484 |
Reported balance
After 2004-04-30 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2004-04-30 · Tax withholding · Disposed 7,591 · Balance 222,484 F1: These are holdings as of Mr. Begley's last day as Abbott Laboratories' Senior Vice President, Hospital Products, as a result of the April 30, 2004 spin-off of Hospira, Inc. from Abbott Laboratories. Mr. Begley is Chief Executive Officer of Hospira, Inc. |
| Common SharesSEC Table I · non-derivative | Indirectprofit sharing trust | 14,009 |
Reported balance
Holding disclosure · report date 2004-04-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 14,009 F1: These are holdings as of Mr. Begley's last day as Abbott Laboratories' Senior Vice President, Hospital Products, as a result of the April 30, 2004 spin-off of Hospira, Inc. from Abbott Laboratories. Mr. Begley is Chief Executive Officer of Hospira, Inc. F2: Balance in the Abbott Laboratories Stock Retirement Trust as of April 30, 2004. |
Filing footnotes · ownership attribution and instrument terms
F1: These are holdings as of Mr. Begley's last day as Abbott Laboratories' Senior Vice President, Hospital Products, as a result of the April 30, 2004 spin-off of Hospira, Inc. from Abbott Laboratories. Mr. Begley is Chief Executive Officer of Hospira, Inc.
F2: Balance in the Abbott Laboratories Stock Retirement Trust as of April 30, 2004.
HANGER, INC.
Report date October 03, 2022 · Filed October 04, 2022
Section 16 reporting ended · disclosed 2022-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 76,414 · Balance 0 F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2018 Filed Jul 3, 2018 20:04 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 211.393 | $0.00 Strike: $112.35 | $0.00 |
DisclosureSEC source: 0000911916-18-000131 · edgar.xml · derivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,755.435 Underlying: Common Stock · 211.393 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| May 16, 2018 Filed May 17, 2018 13:54 UTC | HANGER, INC. HNGR · Entity 14115 | GrantCommon Stock | 7,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-024367 · doc1.xml · nonDerivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,872 F1 · shares: Consists of shares of restricted stock granted under the Company's 2016 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 16, 2019, subject to certain provisions of the Plan. Read SEC document |
| May 15, 2018 Filed May 17, 2018 18:12 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,143.159 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-18-000119 · edgar.xml · derivative · entry 2 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,285.759 Underlying: Common Stock · 1,143.159 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 15, 2018 Filed May 17, 2018 18:12 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $113.72 | $0.00 |
DisclosureSEC source: 0000911916-18-000119 · edgar.xml · derivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,544.042 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F4 · balance_after: Includes 16.120 phantom stock units accrued on April 30, 2018 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 19:07 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 218.672 | $0.00 Strike: $108.61 | $0.00 |
DisclosureSEC source: 0000911916-18-000102 · edgar.xml · derivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,027.922 Underlying: Common Stock · 218.672 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 14.271 phantom stock units accrued on January 29, 2018 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 18:26 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 195.812 | $0.00 Strike: $121.29 | $0.00 |
DisclosureSEC source: 0000911916-18-000011 · edgar.xml · derivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,794.979 Underlying: Common Stock · 195.812 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 14.813 phantom stock units accrued on October 27, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 12:47 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 204.266 | $0.00 Strike: $116.27 | $0.00 |
DisclosureSEC source: 0000911916-17-000232 · edgar.xml · derivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,584.354 Underlying: Common Stock · 204.266 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 14.220 phantom stock units accrued on July 28, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:49 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 184.954 | $0.00 Strike: $128.41 | $0.00 |
DisclosureSEC source: 0000911916-17-000208 · edgar.xml · derivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,365.868 Underlying: Common Stock · 184.954 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:53 UTC | HANGER, INC. HGR · Entity 14115 | GrantCommon Stock | 10,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022011 · doc1.xml · nonDerivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,200 F1 · shares: Consists of shares of restricted stock granted under the Company's 2016 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 19, 2018, subject to certain provisions of the Plan. Read SEC document |
| May 12, 2017 Filed May 16, 2017 18:16 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,067.85 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-17-000178 · edgar.xml · derivative · entry 2 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,142.6 Underlying: Common Stock · 1,067.85 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 12, 2017 Filed May 16, 2017 18:16 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $121.74 | $0.00 |
DisclosureSEC source: 0000911916-17-000178 · edgar.xml · derivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,180.914 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director ("Annual Deferred Share Units"). F4 · balance_after: Includes 13.507 phantom stock units accrued on April 28, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 19:03 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 195.489 | $0.00 Strike: $121.49 | $0.00 |
DisclosureSEC source: 0000911916-17-000139 · edgar.xml · derivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667.407 Underlying: Common Stock · 195.489 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 12.815 phantom stock units accrued on January 27, 2017 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 20:42 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 229.713 | $0.00 Strike: $103.39 | $0.00 |
DisclosureSEC source: 0000911916-17-000002 · edgar.xml · derivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459.103 Underlying: Common Stock · 229.713 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 11.855 phantom stock units accrued on October 28, 2016 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 15:09 UTC | Covista Inc. DV · Entity 3964 | GrantCommon Stock | 3,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-066823 · form4.xml · nonDerivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,057 F1 · security: The common stock is a restricted stock unit which represents a right to receive one share of common stock for each restricted stock unit. Stock units vest 100% on the one year anniversary of the transaction date. Read SEC document |
| November 05, 2016 Filed Nov 7, 2016 21:37 UTC | Covista Inc. DV · Entity 3964 | Tax withholdingCommon Stock | 1,018 | $23.05 | $23,464.90 |
DisclosureSEC source: 0001127602-16-066246 · form4.xml · nonDerivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,417 Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 20:17 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 183.582 | $0.00 Strike: $129.37 | $0.00 |
DisclosureSEC source: 0000911916-16-000660 · edgar.xml · derivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,217.535 Underlying: Common Stock · 183.582 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 10.803 phantom stock units accrued on July 29, 2016 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| April 30, 2004 Filed May 4, 2004 20:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon Shares | 7,591 | $41.47 | $314,760.82 |
DisclosureSEC source: 0001104659-04-012461 · a4.xml · nonDerivative · entry 3 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,484 F1 · balance_after: These are holdings as of Mr. Begley's last day as Abbott Laboratories' Senior Vice President, Hospital Products, as a result of the April 30, 2004 spin-off of Hospira, Inc. from Abbott Laboratories. Mr. Begley is Chief Executive Officer of Hospira, Inc. Read SEC document |
| April 30, 2004 Filed May 4, 2004 20:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon Shares | 10,543 | $41.47 | $437,165.50 |
DisclosureSEC source: 0001104659-04-012461 · a4.xml · nonDerivative · entry 2 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,075 Read SEC document |
| April 30, 2004 Filed May 4, 2004 20:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon Shares | 3,506 | $41.47 | $145,376.29 |
DisclosureSEC source: 0001104659-04-012461 · a4.xml · nonDerivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,618 Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $43.66 | $0.00 |
DisclosureSEC source: 0001104659-04-005600 · a4.xml · derivative · entry 3 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: common shares · 55,000 shares Expires 2014-02-19 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16b under Rule 16b-3. The option becomes exercisable in annual increments of 18,334 on 2/20/05, 18,333 on 2/20/06 and 18,333 on 2/20/07. Read SEC document |
| February 20, 2004 Filed Feb 24, 2004 21:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 8,000 | $43.66 | $349,280.00 |
DisclosureSEC source: 0001104659-04-005600 · a4.xml · nonDerivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,124 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16b under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2004 Filed Feb 18, 2004 23:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 26,381 | $0.00 Strike: $44.31 | $0.00 |
DisclosureSEC source: 0001104659-04-005011 · a4.xml · derivative · entry 5 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,381 Underlying: common shares · 26,381 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 17, 2004 Filed Feb 18, 2004 23:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 29,999 | $0.00 Strike: $35.36 | $0.00 |
DisclosureSEC source: 0001104659-04-005011 · a4.xml · derivative · entry 4 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,001 Underlying: common shares · 29,999 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2004 Filed Feb 18, 2004 23:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 26,381 | $44.31 | $1,168,942.11 |
DisclosureSEC source: 0001104659-04-005011 · a4.xml · nonDerivative · entry 2 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,124 Read SEC document |
| February 17, 2004 Filed Feb 18, 2004 23:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 29,999 | $35.36 | $1,060,764.64 |
DisclosureSEC source: 0001104659-04-005011 · a4.xml · nonDerivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2003 Filed Feb 13, 2004 20:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Giftcommon shares without par value | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-04-004264 · a5.xml · nonDerivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,506 Read SEC document |
| June 30, 2003 Filed Jul 2, 2003 19:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOpton (right to buy) · Derivative | 26,059 | $0.00 Strike: $43.60 | $0.00 |
DisclosureSEC source: 0001104659-03-013886 · j2758_4.xml · derivative · entry 4 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,059 Underlying: Common Shares · 26,059 shares Expires 2010-02-10 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| June 30, 2003 Filed Jul 2, 2003 19:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $34.70 | $0.00 |
DisclosureSEC source: 0001104659-03-013886 · j2758_4.xml · derivative · entry 3 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 30,000 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2003 Filed Jul 2, 2003 19:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 26,059 | $43.60 | $1,136,172.40 |
DisclosureSEC source: 0001104659-03-013886 · j2758_4.xml · nonDerivative · entry 2 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,821 F1 · balance_after: The reporting person also owns 13,771 shares indirectly through the Abbott Laboratories Stock Retirement Trust as of June 30, 2003. Read SEC document |
| June 30, 2003 Filed Jul 2, 2003 19:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 30,000 | $34.70 | $1,041,000.00 |
DisclosureSEC source: 0001104659-03-013886 · j2758_4.xml · nonDerivative · entry 1 BEGLEY CHRISTOPHER B · CIK 0001239420 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.